Search research articles
Contact Us
Filters
Showing results (531-540 of 713) with videos related to
Page
of 72
Sort By:
Cancer Chemotherapy and Pharmacology
|
January 8, 2021
Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
Dongwoo Kang, Elizabeth Ludwig, David Jaworowicz, et al.
Blood
|
June 7, 2003
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
Hagop Kantarjian, Varsha Gandhi, Jorge Cortes, et al.
Cancer
|
March 27, 2015
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia
Tapan M Kadia, Stefan Faderl, Farhad Ravandi, et al.
Journal of Hematology & Oncology
|
October 5, 2014
Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
Sanam Loghavi, Zhuang Zuo, Farhad Ravandi, et al.
Blood
|
April 17, 2009
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
Hagop Kantarjian, Jorge Cortes, Dong-Wook Kim, et al.
American Journal of Hematology
|
July 21, 2018
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia
Maro Ohanian, Guillermo Garcia-Manero, Mark Levis, et al.
Cancer Chemotherapy and Pharmacology
|
April 24, 2013
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies
Daryl Sonnichsen, David J Dorer, Jorge Cortes, et al.
American Journal of Hematology
|
April 4, 2017
Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents
Ana Alfonso, Guillermo Montalban-Bravo, Koichi Takahashi, et al.
American Journal of Hematology
|
April 30, 2014
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia
Ohad Benjamini, Theresa Liu Dumlao, Hagop Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2005
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
William Wierda, Susan O'Brien, Sijin Wen, et al.
Page
of 72
Search research articles
Search
Showing results (531-540 of 713) with videos related to
Sort By:
Page
of 72
Cancer Chemotherapy and Pharmacology
|
January 8, 2021
Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
Dongwoo Kang, Elizabeth Ludwig, David Jaworowicz, et al.
Blood
|
June 7, 2003
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
Hagop Kantarjian, Varsha Gandhi, Jorge Cortes, et al.
Cancer
|
March 27, 2015
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia
Tapan M Kadia, Stefan Faderl, Farhad Ravandi, et al.
Journal of Hematology & Oncology
|
October 5, 2014
Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
Sanam Loghavi, Zhuang Zuo, Farhad Ravandi, et al.
Blood
|
April 17, 2009
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
Hagop Kantarjian, Jorge Cortes, Dong-Wook Kim, et al.
American Journal of Hematology
|
July 21, 2018
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia
Maro Ohanian, Guillermo Garcia-Manero, Mark Levis, et al.
Cancer Chemotherapy and Pharmacology
|
April 24, 2013
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies
Daryl Sonnichsen, David J Dorer, Jorge Cortes, et al.
American Journal of Hematology
|
April 4, 2017
Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents
Ana Alfonso, Guillermo Montalban-Bravo, Koichi Takahashi, et al.
American Journal of Hematology
|
April 30, 2014
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia
Ohad Benjamini, Theresa Liu Dumlao, Hagop Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2005
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
William Wierda, Susan O'Brien, Sijin Wen, et al.
Page
of 72